Scientists track patients for 15 years after revolutionary gene therapy
NCT ID NCT06155500
Summary
This study is following 4 patients for 15 years after they received an experimental gene therapy for sickle cell disease. The therapy involves editing a patient's own blood stem cells to produce fetal hemoglobin, which can help control the disease. Researchers are monitoring long-term safety and whether the treatment effects last over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
St Jude Childrens Research Hospital
Memphis, Tennessee, 38105, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.